1-8 of 8
Dae Ho Lee
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

Helena A. Yu, Luis G. Paz-Ares, James Chih-Hsin Yang, Ki Hyeong Lee, Pilar Garrido, Keunchil Park, Joo-Hang Kim, Dae Ho Lee, Huzhang Mao, Sameera R. Wijayawardana, Ling Gao, Rebecca R. Hozak, Bo H. Chao, David Planchard
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 992–1002.
https://doi.org/10.1158/1078-0432.CCR-20-1690
Published: 15 February 2021
View article titled, Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <em>EGFR</em>-mutant Non–small Cell Lung Cancer
Open the PDF for Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <em>EGFR</em>-mutant Non–small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

FDG-PET as a Potential Tool for Selecting Patients with Advanced Non–Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy

Dok Hyun Yoon, Sora Baek, Chang-Min Choi, Dae Ho Lee, Cheolwon Suh, Jin-Sook Ryu, Dae Hyuk Moon, Jung Shin Lee, Sang-We Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5093–5100.
https://doi.org/10.1158/1078-0432.CCR-10-2791
Published: 31 July 2011
View article titled, FDG-PET as a Potential Tool for Selecting Patients with Advanced Non–Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy
Open the PDF for FDG-PET as a Potential Tool for Selecting Patients with Advanced Non–Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Gefitinib versus Docetaxel for Previously Treated NSCLC—Response

Dae Ho Lee, Sang-We Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (13): 4611.
https://doi.org/10.1158/1078-0432.CCR-11-0901
Published: 05 July 2011
View article titled, Gefitinib versus Docetaxel for Previously Treated NSCLC—Response
Open the PDF for Gefitinib versus Docetaxel for Previously Treated NSCLC—Response in another window
Journal Articles

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

Dae Ho Lee, Keunchil Park, Joo Hang Kim, Jong-Seok Lee, Sang Won Shin, Jin-Hyoung Kang, Myung-Ju Ahn, Jin Seok Ahn, Cheolwon Suh, Sang-We Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1307–1314.
https://doi.org/10.1158/1078-0432.CCR-09-1903
Published: 15 February 2010
View article titled, Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
Open the PDF for Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy in another window
Journal Articles

[18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung

Hee-Jung Sohn, You-Jung Yang, Jin-Sook Ryu, Seung Jun Oh, Ki Chun Im, Dae Hyuk Moon, Dae Ho Lee, Cheolwon Suh, Jung-Shin Lee, Sang-We Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (22): 7423–7429.
https://doi.org/10.1158/1078-0432.CCR-08-0312
Published: 14 November 2008
View article titled, [<sup>18</sup>F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung
Open the PDF for [<sup>18</sup>F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung in another window
Includes: Supplementary data
Journal Articles

A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer

Dae Ho Lee, Sang-We Kim, Kyun-Seop Bae, Jeong-Sook Hong, Cheolwon Suh, Yoon-Koo Kang, Jung-Shin Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (20): 6182–6186.
https://doi.org/10.1158/1078-0432.CCR-07-0534
Published: 18 October 2007
View article titled, A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer
Open the PDF for A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer in another window
Journal Articles

Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers

Dae Ho Lee, Ji-Youn Han, Hong Gi Lee, Jae Jin Lee, Eun Kyoung Lee, Hyae Young Kim, Hark Kyun Kim, Eun Kyung Hong, Jin Soo Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (8): 3032–3037.
https://doi.org/10.1158/1078-0432.CCR-04-2149
Published: 18 April 2005
View article titled, Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers
Open the PDF for Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers in another window
Journal Articles

A Phase II Study of Weekly Irinotecan and Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer

Ji-Youn Han, Dae Ho Lee, Hyae Young Kim, Eun-A Kim, Jae Jin Lee, So Young Ju, Eun Hee Shin, Jin Soo Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (16): 5909–5914.
Published: 15 December 2003
View article titled, A Phase II Study of Weekly Irinotecan and Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer
Open the PDF for A Phase II Study of Weekly Irinotecan and Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer in another window